Mentored career development in clinical research in non-malignant hematology
指导非恶性血液学临床研究的职业发展
基本信息
- 批准号:7291517
- 负责人:
- 金额:$ 39.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-01 至 2011-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAdvisory CommitteesAmerican Society of HematologyAnticoagulantsAreaBasic ScienceBenignBiomedical ResearchBiometryCaringCellular biologyChildhoodClinicalClinical ResearchClinical Trials DesignClinical and Translational Science AwardsDepthDevelopmentEconomic FactorsEducationEducational CurriculumEligibility DeterminationEnsureEnvironmentEpidemiologyErythrocytesEthical IssuesExposure toFacultyFundingFutureGoalsGrantGrowth FactorHematologistHematologyHematopoietic stem cellsHemostatic functionImmune System DiseasesInstitutesInstitutionKnowledgeLeadLeadershipMainstreamingMedicineMentorsMethodologyMolecularMolecular MedicineMyeloproliferative diseaseNamesNon-MalignantNumbersPediatric HospitalsPennsylvaniaPhiladelphiaPhysiciansProgram DevelopmentPublishingRequest for ApplicationsResearchResearch PersonnelResearch Project GrantsResourcesSECTM1 geneSickle Cell AnemiaSideStem Cell DevelopmentStem cellsStructureSurveysThalassemiaTherapeuticTimeTimeLineTrainingTraining ProgramsTransfusionTranslational ResearchUnited States National Institutes of HealthUniversitiesWorkWritingbasecareerdesignexperiencemedical schoolsmembernext generationoncologypatient oriented researchprogramsrole modeltooltranslational medicine
项目摘要
DESCRIPTION (provided by applicant):
This application describes plans at the University of Pennsylvania and Children's Hospital of Philadelphia to train the next generation of leaders in clinical and translational research in non-malignant hematology. The breadth and depth of the hematology programs, along with additional resources at the University, provide an ideal setting for this career development program, which will be structured to cover four areas including: Hemostasis, Red Cell Disorders, Immune Hematology and Transfusion Medicine, and Stem Cells and Myeloproliferative Disorders. Experienced faculty members will lead each area and aid the Director and Co- Directors in developing a comprehensive curriculum in benign hematology. These faculty will serve as Primary Mentors, and with Secondary Mentors, will train scholars in their areas of expertise. In addtion, the program will utilize the resources within the recently developed Institute for Translational Medicine and Therapeutics. The specific training goals of this program are: 1) To provide broad-based clinical training and exposure to all aspects of pediatric and adult non-malignant hematology; 2) To guide the Scholar in acquiring the knowledge and tools necessary to be a successful clinical or translational researcher, including training in biostatistics, epidemiology, clinical trials design, and in the responsible conduct of research; 3) To develop scholars with a thorough understanding of advances in basic molecular and cell biology relevant to their areas of clinical research focus, and in methodologies used in these areas; 4) To ensure knowledge and understanding of ethical issues in both basic and clinical biomedical research; and, 5) To provide close mentoring of the scholars with defined timelines to meet goals in education, research, and scientific and grant writing, and to provide positive clinical research role models in a supportive academic environment. The program will train future clinical and translational researchers in benign hematology who are equipped with a sophisticated background in basic science and clinical research methodologies. It is anticipated that graduates of this program will be at the leading edge of their research field and ideally situated to compete for further NIH funding and to serve as faculty members in non-malignant hematology in academic centers, training the next generation of non-malignant hematologists.
描述(由申请人提供):
本申请描述了宾夕法尼亚大学和费城儿童医院培养下一代非恶性血液学临床和转化研究领导者的计划。血液学课程的广度和深度,沿着大学的额外资源,为这个职业发展计划提供了理想的环境,该计划将涵盖四个领域,包括:止血,红细胞疾病,免疫血液学和输血医学,干细胞和骨髓增生性疾病。经验丰富的教师将领导每个领域,并协助主任和联合主任制定一个全面的良性血液学课程。这些教师将担任主要导师,并与二级导师,将培训学者在他们的专业领域。此外,该计划将利用最近开发的转化医学和治疗研究所的资源。该计划的具体培训目标是:1)提供广泛的临床培训和接触儿科和成人非恶性血液学的各个方面; 2)指导学者获得成为成功的临床或转化研究人员所需的知识和工具,包括生物统计学,流行病学,临床试验设计和负责任的研究行为的培训; 3)培养学者深入了解与其临床研究重点领域相关的基础分子和细胞生物学进展以及这些领域使用的方法; 4)确保对基础和临床生物医学研究中的伦理问题的了解和理解;和,5)为学者提供密切的指导,确定时间表,以满足教育,研究,科学和赠款写作的目标,并在支持性的学术环境中提供积极的临床研究榜样。该计划将培养未来的良性血液学临床和转化研究人员,他们在基础科学和临床研究方法方面具有复杂的背景。预计该计划的毕业生将处于其研究领域的领先地位,并且非常适合竞争进一步的NIH资金,并在学术中心担任非恶性血液学教师,培养下一代非恶性血液学家。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Barbara A Konkle其他文献
Hepatitis C in haemophilia: time for treatment for all
血友病中的丙型肝炎:所有人都需要接受治疗
- DOI:
10.1111/hae.13183 - 发表时间:
2017 - 期刊:
- 影响因子:3.9
- 作者:
Michael Makris;Barbara A Konkle - 通讯作者:
Barbara A Konkle
Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors
A 型血友病和抑制剂患者难治性出血治疗的案例研究
- DOI:
- 发表时间:
2013 - 期刊:
- 影响因子:3.9
- 作者:
Leonard A. Valentino;G. Allen;Joan Cox Gill;A. Hurlet;Barbara A Konkle;Cindy A. Leissinger;L. Luchtman;Jerry S Powell;M. Reding;K. Stine - 通讯作者:
K. Stine
A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one‐stage clotting and chromogenic substrate assays at clinical haemostasis laboratories
一项全球比较现场研究,通过临床止血实验室的一步凝血和显色底物测定来评估 efanesoctocog alfa 的因子 VIII 活性
- DOI:
10.1111/hae.14831 - 发表时间:
2023 - 期刊:
- 影响因子:3.9
- 作者:
S. Pipe;Ali Sadeghi;Barbara A Konkle;Steve Kitchen;Claude Negrier;Mingjie Liu;Elena Santagostino;Annemieke Willemze;Lydia Abad;Karin Knobe;Ekta Seth Chhabra - 通讯作者:
Ekta Seth Chhabra
Barbara A Konkle的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Barbara A Konkle', 18)}}的其他基金
von Willebrand Factor in Sickle Cell Disease Pathophysiology
镰状细胞病病理生理学中的冯维勒布兰德因子
- 批准号:
9302585 - 财政年份:2016
- 资助金额:
$ 39.76万 - 项目类别:
A Pilot Study of N-acetylcysteine in Sickle Cell Disease Vaso-Occlusive Crisis
N-乙酰半胱氨酸在镰状细胞病血管闭塞危象中的初步研究
- 批准号:
9126589 - 财政年份:2015
- 资助金额:
$ 39.76万 - 项目类别:
von Willebrand Factor in Sickle Cell Disease Pathophysiology
镰状细胞病病理生理学中的冯维勒布兰德因子
- 批准号:
9000165 - 财政年份:2012
- 资助金额:
$ 39.76万 - 项目类别:
von Willebrand Factor in Sickle Cell Disease Pathophysiology
镰状细胞病病理生理学中的冯维勒布兰德因子
- 批准号:
8606884 - 财政年份:2012
- 资助金额:
$ 39.76万 - 项目类别:
von Willebrand Factor in Sickle Cell Disease Pathophysiology
镰状细胞病病理生理学中的冯维勒布兰德因子
- 批准号:
8793805 - 财政年份:2012
- 资助金额:
$ 39.76万 - 项目类别:
von Willebrand Factor in Sickle Cell Disease Pathophysiology
镰状细胞病病理生理学中的冯维勒布兰德因子
- 批准号:
8258680 - 财政年份:2012
- 资助金额:
$ 39.76万 - 项目类别:
von Willebrand Factor in Sickle Cell Disease Pathophysiology
镰状细胞病病理生理学中的冯维勒布兰德因子
- 批准号:
8427280 - 财政年份:2012
- 资助金额:
$ 39.76万 - 项目类别:
Novel Biomarkers Predictive of Heparin-Induced Thrombocytopenia
预测肝素引起的血小板减少症的新型生物标志物
- 批准号:
7934006 - 财政年份:2009
- 资助金额:
$ 39.76万 - 项目类别:
Novel Biomarkers Predictive of Heparin-Induced Thrombocytopenia
预测肝素引起的血小板减少症的新型生物标志物
- 批准号:
7992566 - 财政年份:2009
- 资助金额:
$ 39.76万 - 项目类别:
Age Dependent Thrombotic Risk Factors in Heparin-induced Thrombocytopenia
肝素诱导的血小板减少症的年龄依赖性血栓形成危险因素
- 批准号:
7499548 - 财政年份:2007
- 资助金额:
$ 39.76万 - 项目类别:
相似海外基金
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
- 批准号:
0451289 - 财政年份:2005
- 资助金额:
$ 39.76万 - 项目类别:
Standard Grant